Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $59.56, but opened at $57.56. Zealand Pharma A/S shares last traded at $57.56, with a volume of 120 shares traded.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Strong Buy".
Check Out Our Latest Stock Analysis on ZLDPF
Zealand Pharma A/S Stock Performance
The firm has a fifty day simple moving average of $63.80 and a 200-day simple moving average of $78.64. The company has a market cap of $4.09 billion, a PE ratio of -23.12 and a beta of 0.68. The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $248.61 million. On average, research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
